

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number  
**WO 01/80251 A2**

(51) International Patent Classification<sup>7</sup>:

**G21F 9/00**

(74) Agents: CHOWDHURY, Tanzina et al.; Mayer, Brown & Platt, 190 S. LaSalle St., Chicago, IL 60603 (US).

(21) International Application Number:

**PCT/US01/12116**

(81) Designated States (*national*): AU, CA, CN, JP, RU.

(22) International Filing Date:

13 April 2001 (13.04.2001)

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(25) Filing Language:

English

**Published:**

— without international search report and to be republished upon receipt of that report

(26) Publication Language:

English

(30) Priority Data:

09/549,871

14 April 2000 (14.04.2000) US

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant: PG RESEARCH FOUNDATION, INC.  
[US/US]; 8205 South Cass Avenue, Suite 111, Darien, IL 60561 (US).

(72) Inventors: HORWITZ, E., Philip; 854 Huntleigh Drive,  
Naperville, IL 60540 (US). HINES, John, J.; 15933 White  
Willow Road, Newark, IL 60541 (US).



**WO 01/80251 A2**

(54) Title: A METHOD FOR ISOLATING AND PURIFYING  $^{90}\text{Y}$  FROM  $^{90}\text{STRONTIUM}$  IN MULTI-CURIE QUANTITIES

(57) Abstract: The invention relates to a process for separating and purifying multi-curie quantities  $^{90}\text{Y}$  of sufficient chemical and radiochemical purity suitable for use in medical applications without a series of  $^{90}\text{Sr}$  selective extraction chromatographic columns while minimizing loss of radioactive  $^{90}\text{Sr}$  parent and waste stream. The process includes dissolving a nitrate salt of an original  $^{90}\text{Sr}$  stock solution in  $\text{H}_2\text{O}$  creating a strontium nitrate solution; acidifying the strontium nitrate solution containing  $^{90}\text{Y}$  with concentrated nitric acid; evaporating the strontium nitrate solution; filtering or centrifuging strontium nitrate solution to separate crystalline  $^{90}\text{Sr}$  nitrate salt from the solution; evaporating the remaining  $^{90}\text{Y}$  enriched supernate to dryness; dissolving the remaining  $^{90}\text{Y}$  enriched supernate in a strong acid; passing the solution through an yttrium selective extraction chromatographic column; rinsing the yttrium selective extraction chromatographic column with strong acid; and eluting yttrium from yttrium selective extraction column with strong acid.


5

**S P E C I F I C A T I O N****A METHOD FOR ISOLATING AND PURIFYING  $^{90}\text{Y}$  FROM  $^{90}\text{STRONTIUM}$  IN MULTI-CURIE QUANTITIES**10 **FIELD OF THE INVENTION**

This invention relates to a new process of separating and purifying multi-curie quantities of yttrium-90 from strontium-90 and other trace elements and impurities while minimizing loss of strontium and amount of waste generated.

**BACKGROUND OF THE INVENTION**

15 Although the possibility of treating rheumatoid arthritis, other inflamed joints, and cancer with yttrium-90 ( $^{90}_{39}\text{Y}$ ) is well known, a cost effective way to separate  $^{90}\text{Y}$  of sufficient purity that minimizes loss of radioactive Sr and does not generate a large waste stream is still needed.  $^{90}\text{Y}$  results from the decay of strontium-90 and  $^{90}\text{Y}$  decays to stable  $^{90}\text{Zr}$  according to the following scheme:



25  $^{90}\text{Y}$  has a relatively short half-life (64.0 h) and maximum beta energy (2.28 MeV) which makes it suitable for a variety of therapeutic uses such as radiolabeling antibodies for tumor therapy or treating liver malignancies.

Although it is known that  $^{90}\text{Y}$  is suitable for immuno radiotherapy, scientists and doctors have encountered numerous difficulties using  $^{90}\text{Y}$  for medical treatments because of the absence of a cost effective way to separate  $^{90}\text{Y}$  of sufficient purity while minimizing loss of

5 radioactive Sr without generating a large waste stream. The following non-exclusive non-exhaustive list of difficulties in separating and purifying  $^{90}\text{Y}$  have limited the application of  $^{90}\text{Y}$  for medical treatment. Although the half-life and decay scheme of  $^{90}\text{Y}$  is appropriate for various radio therapy applications,  $^{90}\text{Y}$  must be capable of being produced in sufficient multi-curie quantities. Furthermore, before  $^{90}\text{Y}$  can be safely used in clinical applications,  $^{90}\text{Y}$  must be  
10 essentially free of  $^{90}\text{Sr}$  and any other trace elements.  $^{90}\text{Y}$  must be free of  $^{90}\text{Sr}$  by at least a factor of  $10^7$  because  $^{90}\text{Sr}$  can suppress bone marrow production.  $^{90}\text{Y}$  must also be free from any trace elements, such as Ca, Cu, Fe, Zn, and Zr, and other impurities because trace elements could interfere with the radio labeling process by competing with  $^{90}\text{Y}$  for binding sites. All of these difficulties must be overcome in a cost effective manner while minimizing loss of valuable  
15 radioactive Sr without generating large amounts of waste.

In the past,  $^{90}\text{Y}$  has been separated from  $^{90}\text{Sr}$  by solvent extraction, ion-exchange, precipitation, and various forms of chromatography, all of which fail to separate  $^{90}\text{Y}$  of sufficient quantity and purity in a cost effective manner that minimizes loss of radioactive Sr and does not generate a large waste stream. Numerous procedures use a cation exchange resin (e.g. Dowex  
20 50) to retain  $^{90}\text{Sr}$ , while the  $^{90}\text{Y}$  is eluted with an aqueous solution such as lactate, acetate, citrate, oxalate, or EDTA. Several of these procedures have been proposed as the basis for a  $^{90}\text{Y}$  generator system.

U.S. Pat. 5,100,585, and U.S. Pat. No. 5,344,623 describe processes for recovering strontium and technetium from acidic feed solutions containing other fission products.  
25

5                  Another process for separating  $^{90}\text{Y}$  from  $^{90}\text{Sr}$  involves extracting  $^{90}\text{Y}$  from a dilute acid solution of  $^{90}\text{Sr}/^{90}\text{Y}$  using bis 2-ethylhexyl phosphoric acid in dodecane. This procedure has the disadvantages of having a limited generator lifespan and accumulating radiolytic by-products in the  $^{90}\text{Sr}$  stock. This process also has the disadvantage of requiring repeated stripping of the initial extractant solution to reduce trace impurities and repeated washing of stock solution to  
10                destroy dissolved organic phosphates.

Kanapilly and Newton (1971) have described a process for separating multi-curie quantities of  $^{90}\text{Y}$  from  $^{90}\text{Sr}$  by precipitating  $^{90}\text{Y}$  as a phosphate. This process, however, requires adding nonradioactive yttrium as a carrier, yielding  $^{90}\text{Y}$  which are obviously not carrier free and hence unsuitable for site specific binding. This and other prior art teach the addition of only  
15                nonradioactive yttrium. This and other prior art do not teach the addition of nonradioactive strontium. In fact, the prior art teaches away from adding nonradioactive strontium.

U.S. Pat.5,368,736 describes a process for isolating  $^{90}\text{Y}$  from a stock solution of  $^{90}\text{Sr}$ . The  $^{90}\text{Sr}$  solution is stored for a sufficient period of time to allow  $^{90}\text{Y}$  ingrowth to occur.  
This process teaches the use of a series of Sr selective columns at the initial stages of the  
20                process. A major disadvantage is that  $^{90}\text{Sr}$  must be stripped off from each of the strontium-selective extraction chromatographic column because  $^{90}\text{Sr}$  is very valuable and it must be recycled to allow for new  $^{90}\text{Y}$  growth.

Unfortunately, all the various methods mentioned above suffer from one or more of the following disadvantages. The first disadvantage of these methods is that the concentration  
25                of trace elements is too high and the trace elements thereby compete with  $^{90}\text{Y}$  for binding sites, resulting in a decrease in  $^{90}\text{Y}$  labeling. Thus, it is necessary to either remove trace elements and

5 other impurities prior to antibody labeling or carry out postlabeling purification. The second  
disadvantage is that ion-exchange resins gradually lose capacity due to radiation damage. As a  
result, ion-exchange is considered suitable only for purifying and separating subcurie quantities  
of  $^{90}\text{Y}$ , which is less than the multi quantities of  $^{90}\text{Y}$  needed for clinical applications. The third  
disadvantage is that separating  $^{90}\text{Y}$  in acceptable purity and quantity while minimizing  $^{90}\text{Sr}$   
10 breakthrough often requires using a series of long ion-exchange columns and impractically large  
volumes of eluent. A need still exists for a cost effective process of separating  $^{90}\text{Y}$  of sufficient  
quality and quantity without a series of  $^{90}\text{Sr}$  selective extraction chromatographic columns while  
minimizing loss of  $^{90}\text{Sr}$  and without generating large amounts of waste and using large volumes  
of eluent.

15 **SUMMARY OF THE INVENTION**

This invention relates to a new process for separating and purifying multi-curie  
quantities  $^{90}\text{Y}$  of sufficient chemical and radiochemical purity suitable for use in medical  
applications without a series of  $^{90}\text{Sr}$  selective extraction chromatographic columns while  
minimizing loss of radioactive  $^{90}\text{Sr}$  parent and waste stream.

20 It is an object of the invention to separate  $^{90}\text{Y}$  from Sr by a highly selective and  
efficient Sr precipitation procedure and using Y selective resins and no Sr selective resins.  
Another object of this invention is to provide a process for separating  $^{90}\text{Y}$  from Sr where  $^{90}\text{Sr}$   
activity in  $^{90}\text{Y}$  is reduced by  $> 10^7$ . It is a further object of the invention to provide a process for  
separating  $^{90}\text{Y}$  with an overall recovery of  $^{90}\text{Y} > 95\%$ . Furthermore, another object of the  
25 invention is to provide a process for separating  $^{90}\text{Y}$  with an overall recovery of  $^{90}\text{Sr} > 99.9\%$  and  
improved purity with each processing run. Furthermore, another object of the invention is to

5 provide a rapid process for separating  $^{90}\text{Y}$  such that waste generation and radiation damage is minimum.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The above-mentioned and other features of the invention will become more apparent and be best understood, together with the description, by reference to the accompanying 10 drawings, in which:

Fig. 1 shows a single column arrangement for isolating  $^{90}\text{Y}$  from  $^{90}\text{Sr}$  in accordance with the following steps: dissolving strontium nitrate in  $\text{H}_2\text{O}$ ; acidifying the strontium nitrate solution with concentrated nitric acid; evaporating said solution; separating  $^{90}\text{Sr}$  from solution by filtering or centrifuging; evaporating the remaining  $^{90}\text{Y}$  enriched supernate; 15 dissolving the remaining  $^{90}\text{Y}$  enriched supernate in 0.1 to 0.2M HCL; passing the supernate through an yttrium selective extraction chromatographic column containing alkyl alkylphosphonic acid; rinsing the yttrium selective extraction chromatographic column with HCL; and removing yttrium from yttrium selective extraction column with 1 to 2M HCL.

Fig. 2 shows a single column arrangement for isolating  $^{90}\text{Y}$  similar to Fig. 1 except that the yttrium selective extraction chromatographic column contains dialkylphosphinic acid instead of alkyl alkylphosphonic acid. 20

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

Figure 1 depicts the new simplified process, with only one chromatographic column, for separating  $^{90}\text{Y}$  of sufficient purify and multi-curie quantity while minimizing loss of 25 radioactive  $^{90}\text{Sr}$ . Initially,  $^{90}\text{Y}$  is separated from approximately 99.7% of the  $^{90}\text{Sr}$  by precipitating the strontium as a nitrate salt from a nitric acid eutectic (16M). Essentially all of the yttrium

5 remains in solution together with any ferric iron and zirconium while the strontium is selectively precipitated out. To reduce the loss of valuable  $^{90}\text{Sr}$  to the yttrium supernate and to increase the ease of handling radioactive multi curie quantities of  $^{90}\text{Y}$ , stable strontium is added to the  $^{90}\text{Sr}$ . At least 80 to 90% of the mass of strontium that is present in the initial  $^{90}\text{Sr}/^{90}\text{Y}$  stock solution should be stable Sr, i.e.,  $^{86,87,88}\text{Sr}$  isotopes. Requiring that 80-90% of the strontium mass be 10 stable strontium isotopes, as opposed to radioactive  $^{90}\text{Sr}$ , reduces the specific activity of the mixture. Minimizing amounts of  $^{90}\text{Sr}$  is crucial if one desires  $^{90}\text{Y}$  suitable for radio therapeutic applications. When  $^{90}\text{Sr}$  is present in great quantity, more steps and materials are needed to separate and purify  $^{90}\text{Y}$ . For example, three Sr selective chromatography columns are used in the process disclosed in US Patent 5,368,736. By contrast, this new process, which minimizes 15 amounts of radioactive  $^{90}\text{Sr}$ , does not require any  $^{90}\text{Sr}$  selective chromatography. This new process thus saves money, space, time, and waste while decreasing  $^{90}\text{Sr}$  contamination.

As shown in Figure 1, precipitating strontium as a nitrate salt is achieved by first dissolving the strontium nitrate salt in  $\text{H}_2\text{O}$ , 1 (Fig. 1). Approximately 10mL of  $\text{H}_2\text{O}$  is used for one gram of Sr as the nitrate salt. If the initial weight of  $^{90}\text{Sr}$  is 20% by mass, one has 28 curies 20 (200 mg) of radioactivity which is a very substantial amount. After dissolving the strontium nitrate in  $\text{H}_2\text{O}$ , 5mL of concentrated nitric acid is added, 2 (Fig. 1), the volume is reduced to 5mL by evaporating, 3 (Fig. 1). Centrifuging or filtering, 4 (Fig. 1), the mixture precipitates approximately 99.7% of the Sr as strontium nitrate. Having started out with 1g of Sr (=1000mg), this means that 99.7% or better of 1g Sr precipitates out. (99.7% of 1g = 997 mg). Hence 997 25 mg of Sr precipitates out and 3 mg of the original starting Sr remains in the supernate. Of the

5      3mg Sr remaining in the supernate, only 0.3 to 0.6 mg are radioactive  $^{90}\text{Sr}$  if the initial mixture contained 10 to 20%  $^{90}\text{Sr}$ , respectively (10% of 3mg =0.3 mg and 20% of 3mg=0.6 mg).

The concentrated nitric acid supernate is evaporated to dryness, 5 (Fig. 1), and the residue dissolved in 2 to 4 mL of 0.05-0.4 M HCl, preferably 0.1M HCl, 6. The acid does not have to be HCl. The acid may be a strong acid consisting of nitric acid ( $\text{HNO}_3$ ), perchlorate ( $\text{HClO}_4$ ), and sulfuric acid ( $\text{H}_2\text{SO}_4$ ). The resultant supernate load, 7, (Fig. 1) is passed through 10 only one extraction chromatographic column, 10 (Fig. 1), (usually only one mL in bed volume) containing an alkyl alkylphosphonic acid extractant sorbed on an inert polymeric support. The extraction chromatographic column containing the alkyl alkylphosphonic acid extractant is highly selective for  $^{90}\text{Y}$ . The alkyl alkylphosphonic acid column selectively retains yttrium 15 while all alkali and alkaline earth metal ions (including valuable  $^{90}\text{Sr}$ ) and divalent transition and post transition metal ions pass through and are recycled back to the  $^{90}\text{Sr}$  stock solution, 7 and 8 (Fig. 1). The yttrium-selective extractant may be obtained from commercially available 2-ethylhexyl 2-ethylhexylphosphonic acid. However, extraction chromatographic columns prepared from the material must undergo extensive purification using selected complexing 20 agents and acids. The length of the carbon chain ( $C_n$ ) in alkyl alkylphosphonic acid can vary. The alkyl alkylphosphophonic acid is preferably selected from any alkyls consisting of  $C_5$ ,  $C_6$ ,  $C_7$ ,  $C_8$ ,  $C_9$ ,  $C_{10}$  and  $C_{11}$ . This description of alkyl alkylphosphonic acid is for purposes of illustration. The description of alkyl alkylphosphonic acid is not exhaustive and does not limit the invention to the chemical structure disclosed. For example, an alkyl alkylphosphonic acid 25 with alkyls greater than eleven carbons or less than five carbons may be used.

5                   Extensive rinsing (e.g. 20 bed volumes) of the alkyl alkylphosphonic acid extraction chromatographic column is carried out with 0.05-0.4 M, preferably 0.1M HCL, 8 (Fig. 1), to reduce any  $^{90}\text{Sr}$  present by at least  $10^4$  and reduce the overall  $^{90}\text{Sr}$  activity by a factor of  $10^7$ . The acid to remove  $^{90}\text{Sr}$  does not have to be HCL. The acid may be a strong acid consisting of nitric acid ( $\text{HNO}_3$ ), perchlorate ( $\text{HClO}_4$ ), and sulfuric acid ( $\text{H}_2\text{SO}_4$ ). Before 10 recycling the  $^{90}\text{Sr}$  that passes thru the yttrium selective column, this very small quantity of Sr can be purified by adding sufficient concentrated nitric acid to bring the final nitrate concentration to 3M  $\text{HNO}_3$  and then passing the resultant solution through a Sr selective column. The addition of the  $^{90}\text{Sr}$  recovered from step 7 and 8 (Fig. 1) to that recovered from step 4 (Fig. 1) gives an overall recovery of  $^{90}\text{Sr} > 99.9\%$ . After rinsing the column,  $^{90}\text{Y}$  is eluted from the yttrium 15 selective column in 4 bed volumes using 0.5-3.0 M, preferably 1 M HCL, 9 (Fig. 1) with an overall recovery of  $^{90}\text{Y} > 95\%$ . Ferric iron and zirconium (IV) are retained on the column. The acid does not have to be HCL. The acid to elute yttrium may be a strong acid consisting of nitric acid ( $\text{HNO}_3$ ), perchlorate ( $\text{HClO}_4$ ), and sulfuric acid ( $\text{H}_2\text{SO}_4$ ). Any trace of organic extractant or degradation products present in the purified  $^{90}\text{Y}$  are removed by passing the solution through a 20 bed of a polymeric support such as Amberchrom XAD-7, step 11 (Fig. 1). Clinical applications require that the  $^{90}\text{Y}$  product be in  $\leq 0.05\text{M}$  HCl making a final evaporation of the  $^{90}\text{Y}$  column strip necessary.

A small variation of the above process may be carried out by replacing the extraction chromatographic column containing the alkyl alkylphosphonic acid extractant 12 (Fig. 25 1), with a column containing a dialkylphosphinic acid extractant 21 (Fig. 2). The length of the carbon chain ( $C_n$ ) in dialkylphosphinic acid may vary. Similar to alkyl alkylphosphonic acid, the

5 dialkylphosphinic acid is preferably selected from any alkyls consisting of C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub> and  
C<sub>11</sub>. The alkyls may be straight chained or branched. This description of dialkylphosphinic acid  
is for purposes of illustration. The description of dialkylphosphinic acid is not exhaustive and  
does not limit the invention to the chemical structure disclosed. For example, a  
10 dialkylphosphinic acid with alkyls greater than eleven carbons or less than five carbons may be  
used. Phosphinic acid extractant is more stable to hydrolysis and radiolysis but requires a much  
lower acidity to effectively retain yttrium. To effectively retain <sup>90</sup>Y (III), a solution containing  
only 0.01M hydrogen ion must be used.

The load for the dialkylphosphinic acid column is prepared by dissolving the  
residue obtained from evaporating the supernate in 0.05-0.4 HCL, preferably 0.1 M HCl, 13  
15 (Fig. 2), and passing this solution through a small (1 to 2mL) bed volume column containing a  
conventional strong base anion exchange resin on the acetate cycle. The acid does not have to be  
HCL. The acid may be a strong acid consisting of nitric acid (HNO<sub>3</sub>), perchlorate (HClO<sub>4</sub>), and  
sulfuric acid (H<sub>2</sub>SO<sub>4</sub>). The chloride in the load solution is replaced by acetate which in turn  
produces acetic acid. Acetic acid solutions are in the correct pH range for loading the  
20 phosphinic acid containing resin.

After loading the yttrium containing solution onto the dialkylphosphinic acid  
extraction chromatographic column, the column is rinsed with 0.005-0.04 HCL, preferably  
0.01M HCL, 19 (Fig. 2) to remove all traces of <sup>90</sup>Sr to give an overall recovery of <sup>90</sup>Sr > 99.9%  
and reduce <sup>90</sup>Sr activity by a factor of 10<sup>4</sup>. The acid to remove <sup>90</sup>Sr does not have to be HCL.  
25 The acid may be a strong acid consisting of nitric acid (HNO<sub>3</sub>), perchlorate (HClO<sub>4</sub>), and  
sulfuric acid (H<sub>2</sub>SO<sub>4</sub>). Yttrium is then eluted from the column using 0.05-0.3 HCL, preferably

5      0.1M HCl, 20 (Fig. 2), with an overall recovery of  $^{90}\text{Y}$  > 95%. The acid to elute does not have  
to be HCl. The acid may be a strong acid consisting of nitric acid ( $\text{HNO}_3$ ), perchlorate  
( $\text{HClO}_4$ ), and sulfuric acid ( $\text{H}_2\text{SO}_4$ ). Any traces of extractant or organic degradation products are  
removed by passing the solution through a bed of polymeric support. Preparation of the final  
0.05M HCl solution may be carried out by dilution.

10     The following tables 1 and 2 describe the behavior of selected metal ions on  
yttrium selective resins. The following data about  $^{90}\text{Y}$  were used to calculate some of the  
information in Tables 1 and 2: Specific activity of  $^{90}\text{Sr}$  ( $t_{1/2} = 28.6$  y) ( $\lambda = 4.61 \times 10^{-8} \text{ min}^{-1}$ ). 139  
Ci/g or 139 milli-Ci/mg. One Curie of  $^{90}\text{Sr} = 7.20$  mg if pure. Specific activity of  $^{90}\text{Y}$  ( $t_{1/2} = 64.1$   
hrs.) ( $\lambda = 1.80 \times 10^{-4} \text{ min}^{-1}$ ). 0.544 Ci/ $\mu\text{g}$ . One curie of  $^{90}\text{Y} = 1.84 \mu\text{g}$ . Table 1 corresponds to  
15    Fig. 1 when the extractant is alkyl alkylphosphonic acid. Table 1 data was collected under the  
following conditions: Alkyl Alkylphosphonic Acid on Amberchrom CG-71, Particle Size 50-  
100 $\mu\text{m}$ , Load 4.0mL of 0.1M HCl, Rinse 2.0mL of 0.1M HCl/fraction, and Strip 2.0mL of  
1.0M HCl/fraction. Table 2 corresponds to Fig. 2 when the extractant is dialkylphosphinic acid.  
Table 2 data was collected under the following conditions: Dialkylphosphinic Acid on  
20    Amberchrom CG-71, Particle Size 50-100 $\mu\text{m}$ , Bed Volume = 1.0mL, 0.7 cm diameter, Flow  
Rate = 1.0mL/sq. cm/min, Load 9mL of ~ 1M Acetic Acid, Rinse 2.0mL of 0.01M HCl/fraction,  
and Strip 2.0mL of 0.1M HCl/fraction.

5

**Table 1. Behavior of Selected Metal Ions on Yttrium Selective Resin**

		Percent of Total Measured in Each Fraction (for Fig. 1)														
		LOAD					RINSE					STRIP				
			1	2	3	4	5		1	2	3	4	5			
10	Al	96	3	1	—	—	—	—	—	—	—	—	—	—	—	
	Fe	0.1	0.03	—	—	—	—	—	—	—	—	—	—	—	—	
	Mn	97	3	—	—	—	—	—	—	—	—	—	—	—	—	
	Cu	96	3	1	—	—	—	—	—	—	—	—	—	—	—	
	Zn	95	4	0.2	0.1	—	—	—	—	—	—	—	—	—	—	
	Sr	93	7	—	—	—	—	—	—	—	—	—	—	—	—	
	Y	—	—	—	—	—	—	—	83	17	0.1	—	—	—	—	
	Zr	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
15	Cd	97	3	—	—	—	—	—	—	—	—	—	—	—	—	
	Pb	96	3	0.3	0.3	0.2	—	0.4	—	—	—	—	—	—	—	

20 Alkyl Alkylphosphonic Acid on Amberchrom CG-71, Particle Size 50-100 $\mu\text{m}$ , Load 4.0mL of 0.1M HCl, Rinse 2.0mL of 1.0M HCL/fraction, and Strip 2.0mL of 0.1M HCL/fraction.

5

**Table 2. Behavior of Selected Metal Ions on Yttrium Selective Resin**

		Percent of Total Measured in Each Fraction (for Fig. 2)														
		LOAD					RINSE					STRIP				
			1	2	3	4	5		1	2	3	4	5			
10	Al	75	14	8	3	—	—	—	—	—	—	—	—	—	—	
	Fe	89	11	—	—	—	—	—	—	—	—	—	—	—	—	
	Mn	89	11	—	—	—	—	—	—	—	—	—	—	—	—	
	Cu	91	9	—	—	—	—	—	—	—	—	—	—	—	—	
	Zn	4	74	10	2	1	—	—	—	—	—	—	—	—	—	
15	Sr	94	6	—	—	—	—	—	—	—	—	—	—	—	—	
	Y	—	—	—	—	—	—	—	76	12	4	5	—	—	—	
	Zr	48	—	—	—	—	—	—	—	—	—	—	—	—	—	
	Cd	90	10	—	—	—	—	—	—	—	—	—	—	—	—	
	Pb	88	12	—	—	—	—	—	—	—	—	—	—	—	—	

20 Dialkylphosphinic Acid on Amberchrom CG-71, Particle Size 50-100 $\mu\text{m}$ , Bed Volume = 1.0mL,  
 0.7 cm diameter, Flow Rate = 1.0mL/sq. cm/min, Load 9mL of ~ 1M Acetic Acid, Rinse 2.0mL  
 of 0.01M HCl/fraction, and Strip 2.0mL of 0.1M HCl/fraction .

The foregoing description of preferred embodiments of the invention has been  
 presented for purposes of illustration and description. It is not intended to be exhaustive or to  
 limit the invention to the precise form disclosed. Many modifications and variations are possible  
 25 in light of the above teaching. For example,  $^{91}\text{Y}$  may be used for other therapeutic uses not  
 mentioned. Various isotopes of yttrium, such as yttrium-87 and yttrium-91, may be purified  
 using the yttrium selective resin as described herein, although modifications of various acid and  
 extractant concentrations and columnar figure might be necessary. The embodiments were

5 chosen and described to best explain the principles of the invention and its practical application and thereby enable others of ordinary skill in the art to best utilize the invention.

CLAIMS.

1. A process for separating and purifying yttrium isotope consisting of either  $^{87}\text{Y}$ ,  $^{90}\text{Y}$ , or  $^{91}\text{Y}$  from strontium-90, comprising:
  - a. dissolving a nitrate salt of an original  $^{90}\text{Sr}$  stock solution in  $\text{H}_2\text{O}$  creating a strontium nitrate solution;
  - b. acidifying said strontium nitrate solution containing  $^{90}\text{Y}$  with concentrated nitric acid;
  - c. evaporating said strontium nitrate solution;
  - d. filtering or centrifuging said strontium nitrate solution to separate crystalline  $^{90}\text{Sr}$  nitrate salt from said solution to make an yttrium enriched supernate ;
  - e. evaporating said yttrium enriched supernate to dryness;
  - f. dissolving said yttrium enriched supernate which is free of nitric acid in a strong acid;
  - g. passing the solution through an yttrium selective extraction chromatographic column such that essentially all the said yttrium isotope is retained while all other trace metals and impurities pass thru and are recycled back to said original Sr stock solution;
  - h. not using a series of strontium selective extraction chromatographic columns;
  - i. rinsing said yttrium selective extraction chromatographic column with a strong acid to remove any remaining  $^{90}\text{Sr}$  which are recycled back to said original  $^{90}\text{Sr}$  stock solution; and

- j. eluting said yttrium isotope from said yttrium selective extraction chromatographic column with a strong acid.
2. A process for separating and purifying said Y isotope as in claim 1 wherein at least 80-90% of the mass of strontium in the initial Sr/Y stock solution is stable Sr.
3. A process for separating and purifying said Y isotope as in claim 1 wherein said strong acids are selected from a group consisting of HCL, Sulfuric acid, perchlorate acid, and nitric acid.
4. A process for separating and purifying said Y isotope as in claim 1 wherein said extractant for said yttrium selective extraction chromatographic column is alkyl alkylphosphonic acid.
5. A process for separating and purifying said Y isotope as in claim 4 wherein said <sup>90</sup>Y enriched nitric acid residue is dissolved in said strong acid being 0.05-0.4M HCL.
6. A process for separating and purifying said Y isotope as in claim 4 wherein any remaining said <sup>90</sup>Sr is recovered from said yttrium selective extraction chromatographic column with said strong acid being 0.05M-0.4M HCL which are recycled back to said original <sup>90</sup>Sr stock solution.
7. A process for separating and purifying said Y isotope as in claim 4 wherein said yttrium is eluted from said yttrium selective extraction chromatographic column with said strong acid being 0.5-3.0 HCL.
8. A process for separating and purifying said Y isotope as in claim 4 wherein said alkyl alkylphosphonic acid is selected from alkyls consisting of C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub> and C<sub>11</sub> straight chained alkanes.

9. A process for separating and purifying said Y isotope as in claim 4 wherein said alkyl alkylphosphonic acid is selected from alkyls consisting of C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub> and C<sub>11</sub> branched alkanes.

10. A process for separating and purifying said Y isotope as in claim 4 wherein said alkyl alkylphosphonic acid are alkyls with C<sub>n</sub> greater than 11.

11. A process for separating and purifying said Y isotope as in claim 4 wherein said alkyl alkylphosphonic acid are alkyls with C<sub>n</sub> less than 5.

12. A process for separating and purifying said Y isotope as in claim 1 wherein said extractant for said yttrium selective extraction chromatographic column is dialkylphosphinic acid.

13. A process for separating and purifying said Y isotope as in claim 12 wherein said <sup>90</sup>Y enriched nitric acid residue is dissolved in said strong acid being 0.05-0.4M HCL.

14. A process for separating and purifying said Y isotope as in claim 12 wherein any remaining said <sup>90</sup>Sr is recovered from said yttrium selective extraction chromatographic column with said strong acid being 0.005-0.04M HCL which are recycled back to said original <sup>90</sup>Sr stock solution.

15. A process for separating and purifying said Y isotope as in claim 12 wherein said wherein said yttrium is eluted from said yttrium selective extraction chromatographic column with said strong acid being 0.05-0.3 M HCL.

16. A process for separating and purifying said Y isotope as in claim 12 wherein said <sup>90</sup>Y enriched nitric acid residue is dissolved in said strong acid being 0.05-0.4M HCL.

17. A process for separating and purifying said Y isotope as in claim 12 wherein said dialkylphosphinic acid is selected from alkyls consisting of C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub> and C<sub>11</sub> straight chained alkanes.


18. A process for separating and purifying said Y isotope as in claim 12 wherein said dialkylphosphinic acid is selected from alkyls consisting of C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, C<sub>8</sub>, C<sub>9</sub>, C<sub>10</sub> and C<sub>11</sub> branched alkanes.

19. A process for separating and purifying said Y isotope as in claim 12 wherein said dialkylphosphinic acid are alkyls with C<sub>n</sub> greater than 11.

20. A process for separating and purifying said Y isotope as in claim 12 wherein said dialkylphosphinic acid are alkyls with C<sub>n</sub> less than 5.

# METHOD FOR THE ISOLATION AND PURIFICATION OF $^{90}\text{Y}$

Figure 1



# METHOD FOR THE ISOLATION AND PURIFICATION OF $^{90}\text{Y}$

Figure 2

